Latest info suggests this claim is true
YOU CAN SAY THIS...
The Food and Drug Administration (FDA) has approved updated COVID-19 vaccines from Pfizer and Moderna. These vaccines target more recent COVID strains (KP.2) and are recommended for everyone over 6 months. The updated vaccines are available in pharmacies, hospitals, and clinics across the United States. For information on where to get vaccinated, visit www.Vaccines.gov.
WHAT WE KNOW
Vaccine protection decreases over time, so staying up to date on COVID vaccinations is important. Both people who have been vaccinated before and people who have had COVID should get the vaccine.
If you’ve had COVID this summer, you will have some immunity to the virus that lasts about three months. If you’ve had COVID, you may wait up to three months after infection to get vaccinated but can get vaccinated any time after you feel better. For most people, the minimum interval between their last 2023–2024 COVID-19 vaccine dose and their 2024–2025 vaccine dose is 2 months. Contact your healthcare provider for more specifics.
The updated COVID vaccines from Pfizer and Moderna are mRNA vaccines and target the KP.2 strain of the Omicron variant. The Novavax vaccine is based on an older vaccine technology and was also approved for use. Lab experiments have shown that all updated COVID vaccines are effective against the current strains.
Anyone 6 months or older can get the Moderna and Pfizer vaccine, and anyone older than 12 can get the Novavax vaccine.
Medicare, Medicaid, and most private insurance cover adult COVID vaccines. Children can get vaccinated for free through the Vaccines for Children program. Community health clinics may offer free or low-cost vaccines to those without insurance or with limited coverage.
UNKNOWNS
The COVID-19 virus is constantly evolving. Scientists are monitoring for new strains that may emerge this winter.
SOURCE
HEARD IT
BELIEVABILITY
HEARD IT FROM
YOU CAN SAY THIS...
The Food and Drug Administration (FDA) has approved updated COVID-19 vaccines from Pfizer and Moderna. These vaccines target more recent COVID strains (KP.2) and are recommended for everyone over 6 months. The updated vaccines are available in pharmacies, hospitals, and clinics across the United States. For information on where to get vaccinated, visit www.Vaccines.gov.
WHAT WE KNOW
Vaccine protection decreases over time, so staying up to date on COVID vaccinations is important. Both people who have been vaccinated before and people who have had COVID should get the vaccine.
If you’ve had COVID this summer, you will have some immunity to the virus that lasts about three months. If you’ve had COVID, you may wait up to three months after infection to get vaccinated but can get vaccinated any time after you feel better. For most people, the minimum interval between their last 2023–2024 COVID-19 vaccine dose and their 2024–2025 vaccine dose is 2 months. Contact your healthcare provider for more specifics.
The updated COVID vaccines from Pfizer and Moderna are mRNA vaccines and target the KP.2 strain of the Omicron variant. The Novavax vaccine is based on an older vaccine technology and was also approved for use. Lab experiments have shown that all updated COVID vaccines are effective against the current strains.
Anyone 6 months or older can get the Moderna and Pfizer vaccine, and anyone older than 12 can get the Novavax vaccine.
Medicare, Medicaid, and most private insurance cover adult COVID vaccines. Children can get vaccinated for free through the Vaccines for Children program. Community health clinics may offer free or low-cost vaccines to those without insurance or with limited coverage.
UNKNOWNS
The COVID-19 virus is constantly evolving. Scientists are monitoring for new strains that may emerge this winter.
SOURCE
HEARD IT
BELIEVABILITY
HEARD IT FROM
Latest info suggests this claim is true
YOU CAN SAY THIS...
On September 6th, the CDC confirmed a human case of bird flu in Missouri. This is the 14th human case of bird flu in the U.S. this year, and the first case where there is no known contact with a sick or infected animal. The person had underlying medical conditions and was hospitalized but has since recovered. There is no evidence of person-to-person transmission associated with this case, and risk to the general public remains low.
WHAT WE KNOW
The week of August 24th, a person with significant underlying health conditions was hospitalized for chest pain, nausea, vomiting, diarrhea, and weakness. The person was not in the intensive care unit. The patient tested positive for flu, and further testing found that it was a H5 bird flu strain. The patient has since fully recovered.
A person who lives with the patient got sick with similar symptoms on the same day as the case. This close contact was not tested and fully recovered. The timing of both people getting sick does not suggest transmission between them, but could suggest a shared source of exposure. It is also possible that the close contact was sick with something different than bird flu.
There is no known source of direct or indirect exposure for this patient. That includes contact with wild birds, domestic poultry, cattle (including raw milk and raw meat), or other wildlife prior to symptoms. There is no evidence of person-to-person transmission at this time, and the CDC reports that the risk to the public remains low.
UNKNOWNS
The Missouri Department of Health in partnership with CDC is still investigating potential sources of exposure for this case.
Information on if the close contact will be given an antibody test for bird-flu has not yet been released.
When the patient who tested positive for bird flu was tested, they had a low viral load which made it difficult to fully sequence the virus’s genome. Partial results show that the strain is similar to those found in cattle. Additional tests are being run.
HEARD IT
BELIEVABILITY
HEARD IT FROM
YOU CAN SAY THIS...
On September 6th, the CDC confirmed a human case of bird flu in Missouri. This is the 14th human case of bird flu in the U.S. this year, and the first case where there is no known contact with a sick or infected animal. The person had underlying medical conditions and was hospitalized but has since recovered. There is no evidence of person-to-person transmission associated with this case, and risk to the general public remains low.
WHAT WE KNOW
The week of August 24th, a person with significant underlying health conditions was hospitalized for chest pain, nausea, vomiting, diarrhea, and weakness. The person was not in the intensive care unit. The patient tested positive for flu, and further testing found that it was a H5 bird flu strain. The patient has since fully recovered.
A person who lives with the patient got sick with similar symptoms on the same day as the case. This close contact was not tested and fully recovered. The timing of both people getting sick does not suggest transmission between them, but could suggest a shared source of exposure. It is also possible that the close contact was sick with something different than bird flu.
There is no known source of direct or indirect exposure for this patient. That includes contact with wild birds, domestic poultry, cattle (including raw milk and raw meat), or other wildlife prior to symptoms. There is no evidence of person-to-person transmission at this time, and the CDC reports that the risk to the public remains low.
UNKNOWNS
The Missouri Department of Health in partnership with CDC is still investigating potential sources of exposure for this case.
Information on if the close contact will be given an antibody test for bird-flu has not yet been released.
When the patient who tested positive for bird flu was tested, they had a low viral load which made it difficult to fully sequence the virus’s genome. Partial results show that the strain is similar to those found in cattle. Additional tests are being run.
HEARD IT
BELIEVABILITY
HEARD IT FROM
This is true
YOU CAN SAY THIS...
On August 14, the WHO made this declaration after confirming the first clade Ib cases of Mpox outside Africa (in Sweden and Pakistan). This clade is different and more serious than the one that caused a public health emergency in 2022. Clade I Mpox is not in the U.S., and the vaccine JYNNEOS is effective against severe disease in both clade I and clade II. Mpox usually requires skin-to-skin contact with an infected person who has an active rash. Consider getting vaccinated if travelling to an Mpox-affected region.
WHAT WE KNOW
The main symptoms of Mpox include a spotted rash that may be painful or itchy with flu-like symptoms. The virus spreads through close contact between two people and can be spread up to four days before symptoms appear. Most people recover fully from infection with clade II of Mpox, which has a survival rate of 99.9%. Those most at risk of severe illness include those with severely weakened immune systems, children younger than 1, pregnant people and people with a history of eczema.
The clade Ib of Mpox that caused the current public health emergency has higher rates of severe illness and death than clade II. Global health authorities are working to get the JYNNEOS Mpox vaccine to people in countries with the highest cases of clade Ib Mpox like the Democratic Republic of Congo. Countries that currently need the vaccine most are having challenges getting it.
In the United States, only Mpox clade II is present. While Mpox can infect anybody, people most at risk of getting Mpox are those with multiple sexual partners. The two-shot JYNNEOS vaccine is approved and available in the U.S. CDC recommends people with multiple sexual partners consider vaccination, and a complete list of guidelines can be found on the CDC’s website.
UNKNOWNS
Vaccination distribution efforts are still underway, and it is still not clear when countries like the Democratic Republic of Congo will be able to administer JYNNEOS vaccines.
SOURCE
HEARD IT
BELIEVABILITY
HEARD IT FROM
YOU CAN SAY THIS...
On August 14, the WHO made this declaration after confirming the first clade Ib cases of Mpox outside Africa (in Sweden and Pakistan). This clade is different and more serious than the one that caused a public health emergency in 2022. Clade I Mpox is not in the U.S., and the vaccine JYNNEOS is effective against severe disease in both clade I and clade II. Mpox usually requires skin-to-skin contact with an infected person who has an active rash. Consider getting vaccinated if travelling to an Mpox-affected region.
WHAT WE KNOW
The main symptoms of Mpox include a spotted rash that may be painful or itchy with flu-like symptoms. The virus spreads through close contact between two people and can be spread up to four days before symptoms appear. Most people recover fully from infection with clade II of Mpox, which has a survival rate of 99.9%. Those most at risk of severe illness include those with severely weakened immune systems, children younger than 1, pregnant people and people with a history of eczema.
The clade Ib of Mpox that caused the current public health emergency has higher rates of severe illness and death than clade II. Global health authorities are working to get the JYNNEOS Mpox vaccine to people in countries with the highest cases of clade Ib Mpox like the Democratic Republic of Congo. Countries that currently need the vaccine most are having challenges getting it.
In the United States, only Mpox clade II is present. While Mpox can infect anybody, people most at risk of getting Mpox are those with multiple sexual partners. The two-shot JYNNEOS vaccine is approved and available in the U.S. CDC recommends people with multiple sexual partners consider vaccination, and a complete list of guidelines can be found on the CDC’s website.
UNKNOWNS
Vaccination distribution efforts are still underway, and it is still not clear when countries like the Democratic Republic of Congo will be able to administer JYNNEOS vaccines.
SOURCE
HEARD IT
BELIEVABILITY
HEARD IT FROM
KNOW
FROM
YOU CAN SAY THIS...
The Food and Drug Administration (FDA) has approved updated COVID-19 vaccines from Pfizer and Moderna. These vaccines target more recent COVID strains (KP.2) and are recommended for everyone over 6 months. The updated vaccines are available in pharmacies, hospitals, and clinics across the United States. For information on where to get vaccinated, visit www.Vaccines.gov.
WHAT WE KNOW
Vaccine protection decreases over time, so staying up to date on COVID vaccinations is important. Both people who have been vaccinated before and people who have had COVID should get the vaccine.
If you’ve had COVID this summer, you will have some immunity to the virus that lasts about three months. If you’ve had COVID, you may wait up to three months after infection to get vaccinated but can get vaccinated any time after you feel better. For most people, the minimum interval between their last 2023–2024 COVID-19 vaccine dose and their 2024–2025 vaccine dose is 2 months. Contact your healthcare provider for more specifics.
The updated COVID vaccines from Pfizer and Moderna are mRNA vaccines and target the KP.2 strain of the Omicron variant. The Novavax vaccine is based on an older vaccine technology and was also approved for use. Lab experiments have shown that all updated COVID vaccines are effective against the current strains.
Anyone 6 months or older can get the Moderna and Pfizer vaccine, and anyone older than 12 can get the Novavax vaccine.
Medicare, Medicaid, and most private insurance cover adult COVID vaccines. Children can get vaccinated for free through the Vaccines for Children program. Community health clinics may offer free or low-cost vaccines to those without insurance or with limited coverage.
UNKNOWNS
The COVID-19 virus is constantly evolving. Scientists are monitoring for new strains that may emerge this winter.
SOURCES
HEARD IT
heard this concern.
BELIEVABILITY
HEARD IT FROM
KNOW
FROM
YOU CAN SAY THIS...
On September 6th, the CDC confirmed a human case of bird flu in Missouri. This is the 14th human case of bird flu in the U.S. this year, and the first case where there is no known contact with a sick or infected animal. The person had underlying medical conditions and was hospitalized but has since recovered. There is no evidence of person-to-person transmission associated with this case, and risk to the general public remains low.
WHAT WE KNOW
The week of August 24th, a person with significant underlying health conditions was hospitalized for chest pain, nausea, vomiting, diarrhea, and weakness. The person was not in the intensive care unit. The patient tested positive for flu, and further testing found that it was a H5 bird flu strain. The patient has since fully recovered.
A person who lives with the patient got sick with similar symptoms on the same day as the case. This close contact was not tested and fully recovered. The timing of both people getting sick does not suggest transmission between them, but could suggest a shared source of exposure. It is also possible that the close contact was sick with something different than bird flu.
There is no known source of direct or indirect exposure for this patient. That includes contact with wild birds, domestic poultry, cattle (including raw milk and raw meat), or other wildlife prior to symptoms. There is no evidence of person-to-person transmission at this time, and the CDC reports that the risk to the public remains low.
UNKNOWNS
The Missouri Department of Health in partnership with CDC is still investigating potential sources of exposure for this case.
Information on if the close contact will be given an antibody test for bird-flu has not yet been released.
When the patient who tested positive for bird flu was tested, they had a low viral load which made it difficult to fully sequence the virus’s genome. Partial results show that the strain is similar to those found in cattle. Additional tests are being run.
SOURCES
HEARD IT
heard this concern.
BELIEVABILITY
HEARD IT FROM
KNOW
FROM
YOU CAN SAY THIS...
On August 14, the WHO made this declaration after confirming the first clade Ib cases of Mpox outside Africa (in Sweden and Pakistan). This clade is different and more serious than the one that caused a public health emergency in 2022. Clade I Mpox is not in the U.S., and the vaccine JYNNEOS is effective against severe disease in both clade I and clade II. Mpox usually requires skin-to-skin contact with an infected person who has an active rash. Consider getting vaccinated if travelling to an Mpox-affected region.
WHAT WE KNOW
The main symptoms of Mpox include a spotted rash that may be painful or itchy with flu-like symptoms. The virus spreads through close contact between two people and can be spread up to four days before symptoms appear. Most people recover fully from infection with clade II of Mpox, which has a survival rate of 99.9%. Those most at risk of severe illness include those with severely weakened immune systems, children younger than 1, pregnant people and people with a history of eczema.
The clade Ib of Mpox that caused the current public health emergency has higher rates of severe illness and death than clade II. Global health authorities are working to get the JYNNEOS Mpox vaccine to people in countries with the highest cases of clade Ib Mpox like the Democratic Republic of Congo. Countries that currently need the vaccine most are having challenges getting it.
In the United States, only Mpox clade II is present. While Mpox can infect anybody, people most at risk of getting Mpox are those with multiple sexual partners. The two-shot JYNNEOS vaccine is approved and available in the U.S. CDC recommends people with multiple sexual partners consider vaccination, and a complete list of guidelines can be found on the CDC’s website.
UNKNOWNS
Vaccination distribution efforts are still underway, and it is still not clear when countries like the Democratic Republic of Congo will be able to administer JYNNEOS vaccines.
SOURCES
HEARD IT
heard this concern.
BELIEVABILITY
HEARD IT FROM
